The current modalities utilized for tracking the progression of AD are principally reliant on imaging techniques – specifically, volumetric magnetic resonance imaging (MRI) (3) and positron emission tomography (PET) (4) – that facilitate the visual assessment of metabolically active or aggregated Aβ and tau within the brain, as well as cerebrospinal fluid (CSF) biomarkers indicative of Aβ42 and phosphorylated tau (5, 6). The gene discussed is MAPT; the disease is Alzheimer disease.